| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_88bd3d3ca5517d8644a108fe356e5c3a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e13cf25eb1bef6199475314477618b46 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06T11-001
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06T2200-24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06T13-80
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6889
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06T11-203
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06T11-60 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G06T11-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G06T11-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G06T13-80 |
| filingDate |
2022-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9eeef637b111284a354294da8c29a35c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0f04187ab16ce9de1559ad6ed1a04eb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_644a412bf0a957fdf65b699fab85d485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e23bef5e7188d8a2e5a8c00c8b6cc65e |
| publicationDate |
2022-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022172420-A1 |
| titleOfInvention |
Anti-her3 antibody-drug conjugate |
| abstract |
To provide an antitumor drug having excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. Provided is an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER3 antibody via a linker having a structure represented by the formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(═O)— or -L1-L2-LP- (the anti-HER3 antibody is connected to the terminal of L1, the antitumor compound is connected to the carbonyl group of —(CH2)n2-C(═O)— moiety or the C terminal of LP, with the nitrogen atom of the amino group at position 1 as a connecting position). |
| priorityDate |
2014-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |